Jasper Therapeutics Appoints New CMO, Director
Ticker: JSPRW · Form: 8-K · Filed: Jun 20, 2024 · CIK: 1788028
| Field | Detail |
|---|---|
| Company | Jasper Therapeutics, Inc. (JSPRW) |
| Form Type | 8-K |
| Filed Date | Jun 20, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $115.00, $23 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, board-election, personnel-change
Related Tickers: JSPR
TL;DR
Jasper Therapeutics beefs up leadership with a new CMO and board member.
AI Summary
Jasper Therapeutics, Inc. announced on June 17, 2024, the appointment of Dr. Jonathan Leipsic as Chief Medical Officer and the election of Ms. Sarah K. Johnson to its Board of Directors. The company also disclosed compensatory arrangements for its named executive officers, details of which are included in the filing.
Why It Matters
The appointment of a new Chief Medical Officer and a board member can signal strategic shifts in the company's research and development direction or governance.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can indicate significant strategic shifts or internal challenges within a company.
Key Players & Entities
- Jasper Therapeutics, Inc. (company) — Registrant
- Dr. Jonathan Leipsic (person) — Appointed Chief Medical Officer
- Ms. Sarah K. Johnson (person) — Elected to Board of Directors
- June 17, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer of Jasper Therapeutics?
Dr. Jonathan Leipsic has been appointed as the new Chief Medical Officer of Jasper Therapeutics.
Who has been elected to the Board of Directors of Jasper Therapeutics?
Ms. Sarah K. Johnson has been elected to the Board of Directors of Jasper Therapeutics.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is June 17, 2024.
What other information is disclosed regarding executive compensation?
The filing discloses compensatory arrangements for certain officers.
What is the former name of Jasper Therapeutics, Inc.?
The former name of Jasper Therapeutics, Inc. was Amplitude Healthcare Acquisition Corp.
Filing Stats: 1,115 words · 4 min read · ~4 pages · Grade level 10.6 · Accepted 2024-06-20 06:02:52
Key Financial Figures
- $0.0001 — tered) Voting Common Stock, par value $0.0001 per share JSPR The Nasdaq Stock Mar
- $115.00 — ng Common Stock at an exercise price of $115.00 JSPRW The Nasdaq Stock Market LLC
- $23 — as an exercise price per share equal to $23.19, the closing price of the Company's
Filing Documents
- ea0208074-8k_jasper.htm (8-K) — 36KB
- ea020807401ex99-1_jasper.htm (EX-99.1) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- 0001213900-24-053982.txt ( ) — 281KB
- jspr-20240617.xsd (EX-101.SCH) — 4KB
- jspr-20240617_def.xml (EX-101.DEF) — 26KB
- jspr-20240617_lab.xml (EX-101.LAB) — 36KB
- jspr-20240617_pre.xml (EX-101.PRE) — 25KB
- ea0208074-8k_jasper_htm.xml (XML) — 6KB
02. Departure of Directors or Certain Officers; Election
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 17, 2024, Anna French, D.Phil. notified the Board of Directors (the "Board") of Jasper Therapeutics, Inc. (the "Company") of her intent to resign from the Board effective as of June 18, 2024. Dr. French's decision to resign was not due to any disagreement with the Company on any matter relating to the Company's operations, policies or practices. Effective immediately following Dr. French's resignation, on June 18, 2024, the Board appointed Svetlana Lucas, Ph.D. as a Class III director of the Company. Dr. Lucas, age 52, has served as the Chief Business Officer at Scribe Therapeutics Inc. since June 2019. Previously, she served as Senior Vice President, Business Development at Tizona Therapeutics, Inc. ("Tizona"), a clinical stage immunotherapy company, from January 2019 to June 2019, where she was responsible for the company's business development strategy and transactions, including global strategic collaboration with AbbVie Inc., and prior to that as Vice President at Tizona from June 2015 to January 2019. Before joining Tizona, Dr. Lucas was Head of Oncology and Inflammation External R&D Team at Amgen Inc. ("Amgen") from August 2014 to July 2015 where she oversaw business development activities, including Amgen's strategic cancer immunotherapy research collaboration and licensing agreement with Kite Pharma, and collaborated with Amgen Ventures on several investments in oncology and inflammation. Svetlana joined Amgen following the acquisition of Onyx Pharmaceuticals, Inc. ("Onyx"), where she served as a Director, Corporate Development from September 2012 to August 2014 and spearheaded the company's oncology partnering strategy and due diligence of new opportunities. She held positions of increasing responsibility in strategy, business development, and strategic marketing at Amgen from January 2003
01. Other Events
Item 8.01. Other Events. On June 19, 2024, the Company issued a press release announcing the appointment of Dr. Lucas to the Board. A copy of the press release is filed herewith as Exhibit 99.1.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. 99.1 Press release dated June 19, 2024. 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JASPER THERAPEUTICS, INC. Date: June 20, 2024 By: /s/ Herb Cross Name: Herb Cross Title: Chief Financial Officer 3